Tag Archive for: Biologic

2022 has been marked by the first year of leadership under CEO Joaquin Duato and the anticipated separation of the company’s consumer health business.

A separation of Sandoz via a 100 percent spin-off will create the leading European generics company and a global leader in biosimilars, and a more focused Novartis.

The FDA’s nod extends Benlysta’s indication in the US, making it the first approved treatment for pediatric lupus nephritis. Benlysta was also the first approved targeted therapy for lupus nephritis in adults in 2011.

The U.S. Food and Drug Administration (FDA) approved Dupixent (dupilumab) for children aged 6 months to 5 years with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.